Company
Company Overview
Ricoh Biosciences, K.K. is a wholly-owned subsidiary of Ricoh Biosciences, Inc. headquartered in Baltimore, Maryland, USA, with its base located in the Shonan Health Innovation Park in Fujisawa, Kanagawa Prefecture.
| Company Name | Ricoh Biosciences, K.K. |
| CEO | Daisuke Takagi |
Location
Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan
History
Established Elixirgen Scientific, Inc. Japan Branch in Yokohama, Kanagawa.
Relocated the Japan Branch to the Life Innovation Center in Kawasaki.
Expanded into Shonan Health Innovation Park in Fujisawa and launched mRNA CDMO services.
Incorporated as Elixirgen Scientific Japan, Inc.
Acquisition of additional shares in a consolidated subsidiary by Ricoh Company, Ltd. and conversion of the subsidiary into a wholly owned subsidiary.
Business Overview
- ）mRNA Contract Development & Manufacturing (CDMO) Services
- ）iPS Cell Differentiation Service
Philosophy
Through mRNA and iPSC related technologies, we contribute to human health and welfare.
Our mission is to leverage cutting-edge biotechnology to support the development of innovative pharmaceuticals and medical technologies, thereby improving health and welfare worldwide. We engage sincerely with our clients’ needs and strive to be a trusted partner by delivering high-quality products and services.
Our Strengths
- Domestic cGMP-compliant mRNA manufacturing facility in Japan
- Extensive experience and track record
- Technical expertise that ensures high-quality products
- Flexible response to customer needs
Management Team
Daisuke Takagi
President
Joined Applied Materials Japan, where he was responsible for the development of copper wiring formation processes and equipment development at both the company and Ebara Corporation. He also served as the joint research coordinator in Dresden, Germany.
Subsequently, as a new business development manager at a venture company, he experienced the listing on the Tokyo Stock Exchange Mothers market. Joined Ricoh Co., Ltd., where he launched a new material development project for printers, and in 2013, launched a bio-3D printing project and participated in an AMED project.
Joined Elixagen Scientific Co., Ltd. in 2019, and launched the CDMO business in February 2021, contributing to the expansion of the CDMO business by supporting customers from the early stages of drug discovery projects.
Appointed President and CEO in October 2024.
Hidemitsu Higashi
Executive Vice President, Manufacturing Site Manager
Completed the Master's program at the Graduate School of Biosphere Sciences, Hiroshima University. Joined a domestic pharmaceutical company and gained over 25 years of experience in pharmaceutical research and development.
Served as a project leader for multiple drug discovery projects, a manager responsible for strategic planning and project management in R&D, and a manager promoting open innovation. Also held the position of Product Strategy Director for the regenerative medicine division of a subsidiary within the group.
At Ricoh Co., Ltd., served as a department head responsible for a joint venture with Elixirgen Scientific, Inc. Appointed as Vice President of Elixirgen Scientific Japan Co., Ltd. in October 2024.
Kazuhiro Aiba
Vice President of iPSC division
Ph.D. in Biological Sciences, Graduate School of Biological Sciences, University of Tsukuba.
Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellow, ERATO Researcher, Visiting Researcher at the National Institute on Aging (NIA), National Institutes of Health (NIH), USA, Principal Researcher at the Stem Cell Drug Discovery Research Institute (NPO), Associate Professor at the Center for Integrated Systems of Matter and Cells, Kyoto University, and CTO at Stem Cell & Device Research Institute Co., Ltd., before joining Elixirgen Scientific, Inc. in 2019, where he served as Representative of the Japan Branch, and assumed his current position in 2022.
Since his NIA fellowship, he has been engaged in stem cell research, and upon returning to Japan, he has conducted research and development of disease model cells using neural cells differentiated from human embryonic stem cells and human iPS cells.
